ZenComplete™: Human Islet Assays
The global prevalence of diabetes mellitus has reached epidemic proportions and is projected to continue to rise for the foreseeable future. It is estimated that diabetes will be the 7th leading cause of death worldwide by 2030. Both major forms of diabetes mellitus, type 1 (T1D) and type 2 (T2D), are ultimately caused by a failure of pancreatic β-cells to deliver insulin at a rate sufficient to account for metabolic demand. The decline of β-cell function is attributed to either decreased insulin secretion or loss of β-cell mass, lending to loss of glycemic control. Compounds that increase insulin secretion and cell proliferation or decrease cell death may be considered as therapeutic strategies for diabetes.
Islet Cell Proliferation
Cell proliferation can be measured after acute or chronic treatment of islets with compounds. Total islet cell proliferation or cell type-specific proliferation is measured by combining ClickIT technology with insulin and glucagon antibody staining to recognize beta cell-specific or alpha cell-specific proliferation, respectively. The measurement is conducted in a 96-well format with Ad-Cyclin D1 as the positive control and Ad-GFP as the negative control.
Islet Cell Death
Cell death can be measured after acute or chronic treatment of islets with compounds. Total islet cell or cell type-specific death is measured in this assay by utilizing insulin and glucagon antibodies. ImageIT staining is used to measure both necrosis and apoptosis, and TUNEL staining is used to measure only apoptosis. The measurement is conducted in a 96-well format with 10 mM streptozotocin (STZ) as the positive control and untreated cells as the negative control.
ZenComplete: Human Islet Assays
|CA-73||GSIS Assay, Human Islets||96-well plate||Assay||Contact US|
|CA-71||Proliferation Assay-Human Islets||96-well plate||Assay||Contact US|
To learn more about our services, please contact our Services Team